Manufacturing in the Industry 4.0 era: how to balance innovation with performance while not being disrupted


10th March 2021 | 10:00am EST | Christos Varsakelis PhD, Senior Manager Global Data Analytics & Innovation, GSK Vaccines, Belgium |BOOK FREE SEAT FOR THIS WEBINAR

The manufacturing status quo reflects a compromise between innovation and performance. But the battle between these values is perpetual and, in the dawn of Industry 4.0 era, a new compromise between technological progress and the need for stationarity is being crafted. Being able to successfully harvest the benefits of the fourth industrial revolution requires a) separating facts from fiction and b) getting acquainted with the never-before-encountered bottlenecks that will have to be deal with. In this talk, we will go through the unique opportunities and the unprecedented challenges accompanying the fourth industrial revolution. The point of view, however, is not that of the salesman, which is frequently encountered online, but rather of the buyer, i.e. manufacturing.  The objective, therefore, is simple, albeit arduous: transform the buyer of this negotiation table into an informed investor that no-longer faces a competitive disadvantage.

Presented by Christos Varsakelis PhD, Senior Manager Global Data Analytics & Innovation, GSK Vaccines, Belgium

Christos pursued a Ph.D. in fluid mechanics in UCLouvain in Belgium. He is also in hold of a B.A. in Mathematics from the Aristotle University of Thessaloniki, Greece and an M.Sc. in Applied Mathematics from the ETH Zurich, Switzerland. Prior joining GSK Vaccines, Christos worked in Geoconsulting, the stock market and the chemical industry. Since 2018, Christos has been a Senior Manager in Global Analytics and Innovation and his role evolves around innovation intelligence and business development of capabilities for in silico process development. His moto is innovation = cash.

Followed by Mark Demesmaeker, Head of Data Analytics at Sartorius Stedim Biotech

Dr. Mark Demesmaeker is Head of Data Analytics, Sartorius Stedim Data Analytics (SSDA), part of Sartorius-Stedim Biotech. Mark joined SSDA in 2018. He is a life science professional with over 20 years of experience in pharmaceutical R&D, analytics and business intelligence, and has held leadership positions at the World Health Organization, Spotfire, TIBCO Software, IBM, and Integrated Clinical Systems. Most recently, he served as Vice President, Clinical & Translational Analytics at PerkinElmer Informatics. Mark holds a Ph.D. in drug metabolism and pharmacokinetics from the German University of Kiel.

Sponsored by Sartorius Stedim Biotech & Ypso-Facto

About Sartorius

Sartorius Stedim Data Analytics develops software under the Umetrics Suite for design of experiments and multivariate data analysis, for the individual user as well as for on-line continuous and batch processes.
The stability of Umetrics founding principles and the flexibility of our services enables us to promote every way of implementation of design of experiments and multivariate technology that our clients require. We are committed to supporting our clients in their mission to take control over their data flow, by conveying our advanced expertise in advanced data analytics technology. Our mission is to provide comprehensive solutions which create value from data, enabling better decision making and process excellence.

Our market exists in every sector of industry where there are manufacturing, testing or data analysis activities, but historically the highest number of collaborations has been in the life science, semiconductor and chemical industries.

Umetrics is since April 2017 owned by Sartorius Stedim Biotech AS.

 

About Ypso-Facto

Ypso-Facto is a service company offering scientific and technical consulting, and simulation software for your (bio)chemical processes.

We combine strong industrial experience and scientific expertise with a complementary know-how in chemistry/biochemistry, software development and process engineering to develop disruptive simulation software and support innovative processes.

Ypso-Facto offers a unique GPX® approach combining your expertise (Guess), Predictive mechanistic modeling (P) and eXperimental data (X) to address your challenges.

Simulation Software :

We believe that process modeling and simulation is key to design and optimize robust (bio)chemical processes, and move away from the traditional trial-and-error approach.

Hence we designed some innovative software solutions:

  • Ypso-Proxima ®, a Process Evaluation software suite, from experimental Data acquisition, through Process Design, to Cost evaluation.
  • Ypso-Ionic ® , for ion exchange processes simulation.
  • ChromWorks ™, for chromatographic processes simulation.

 

With these powerful and user-friendly software, Ypso-Facto aims at helping the industrial firms enter a new era for the development and production of their (bio)chemical products.

We also propose custom software solution for modeling proprietary or non-conventional processes.

Consulting expertise :

We can assist you through all phases of your project development, from brainstorming to scale-up,  debottlenecking and troubleshooting, but also economic evaluation


We will not sell your information to a third party. See our Privacy Policy